GIST
Here below, you will find a list of all the latest content published on this website on the topic of GIST. The content is published in chronological order. Find out more about our content categorisation.
- Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors (GIST) treated with imatinib (484O)
- Sarcomas and GIST
- ESMO 2017 Highlights in Sarcoma and GIST: Novel Drugs and Networks
- Surgery in the treatment of metastatic and recurrent Gastrointestinal Stromal Tumors
- Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 ye...
- Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): a retrospective analysis.
- Analysis of PD-L1 Expression in Patients with Gastrointestinal Stromal Tumors
- Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for patients with metastatic and/or unresectable gastrointe...
- Serum miRNA abundances discriminate imatinib-naive patients with advanced gastrointestinal stromal tumors (GIST) from those in remission on Imatini...
- LncRNA H19, HOTAIR and MALAT1 as prognostic molecular biomarkers in GIST.
- Gastrointestinal stromal tumors secrete Ghrelin and express ghrelin receptors
- Mutant KIT Translocates into the Nucleus and Induces NFKBIB Expression that Leads to KIT Expression in Imatinib-Resistant Gastrointestinal Stromal...
- Characteristics and prognosis of gastrointestinal stromal tumor in the pre-imatinib era: an analysis based on the Kinki GIST registry in Japan
- Early response evaluation by 18F-FDG-PET influences management in gastrointestinal stromal tumor patients treated with neo-adjuvant intent
- Notch pathway inhibition with LY3039478 in soft tissue sarcoma (STS) and gastrointestinal stromal tumours (GIST)
- Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refract...
- Efficacy and Safety of Palbociclib in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
- Managing GIST resistance to standard TKI therapy
- Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)
- Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an a...
- Adjuvant systemic therapy in STS and GIST for whom?
- GIST
- Sarcoma
- GIST
- PD-1 Inhibitor Therapy Efficacy May Be ‘Limited’ In Soft-Tissue Sarcoma, GIST